CANCER:

Renal Cell Carcinoma

Related cancers:

‹

Kidney Cancer (236)

Kidney Medullary Carcinoma (3)

Kidney Cancer (236)

Kidney Medullary Carcinoma (3)

›

No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab + cabozantinib tablet Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	avelumab + axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	avelumab + axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	sorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	tivozanib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	temsirolimus Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	sunitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	everolimus + lenvatinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	everolimus Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	cabozantinib tablet Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	pembrolizumab + axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	pazopanib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	aldesleukin Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Renal Cell Carcinoma RCC	bevacizumab + erlotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Renal Cell Carcinoma RCC	erlotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pazopanib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	temsirolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	sorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	lenvatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	axitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	tivozanib Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: B - Late Trials
No biomarker No biomarker	Renal Cell Carcinoma RCC	pembrolizumab + lenvatinib Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	nivolumab + cabozantinib tablet Sensitive: B - Late Trials
MET mutation MET mutation	Renal Cell Carcinoma RCC	savolitinib Sensitive: B - Late Trials
No biomarker No biomarker	Renal Cell Carcinoma RCC	MK-6482 Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	pembrolizumab + axitinib Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	bevacizumab + atezolizumab Sensitive: B - Late Trials
ARID1A mutation ARID1A mutation	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials
MTOR mutation MTOR mutation	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials
ROBO3 mutation ROBO3 mutation	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials
FLT1 rs9554320 FLT1 rs9554320	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials
KDR rs2071559 KDR rs2071559	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	nivolumab + ipilimumab Sensitive: B - Late Trials
No biomarker No biomarker	Renal Cell Carcinoma RCC	pembrolizumab Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Renal Cell Carcinoma RCC	dostarlimab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	atezolizumab Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Renal Cell Carcinoma RCC	olaparib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Renal Cell Carcinoma RCC	olaparib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	pembrolizumab Sensitive: C1 - Off-label
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	MK-6482 Sensitive: C2 – Inclusion Criteria
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	PT2385 Sensitive: C2 – Inclusion Criteria
MTOR mutation MTOR mutation	Renal Cell Carcinoma RCC	everolimus Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	avelumab Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Renal Cell Carcinoma RCC	crizotinib Sensitive: C2 – Inclusion Criteria
KIM1 expression KIM1 expression	Renal Cell Carcinoma RCC	CDX-014 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	nivolumab Sensitive: C2 – Inclusion Criteria
FLCN mutation FLCN mutation	Renal Cell Carcinoma RCC	everolimus Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria
MET mutation MET mutation	Renal Cell Carcinoma RCC	cabozantinib capsule Sensitive: C2 – Inclusion Criteria
TFE3 translocation TFE3 translocation	Renal Cell Carcinoma RCC	cabozantinib tablet Sensitive: C2 – Inclusion Criteria
MET mutation MET mutation	Renal Cell Carcinoma RCC	crizotinib Sensitive: C2 – Inclusion Criteria
HDAC2 expression HDAC2 expression	Renal Cell Carcinoma RCC	pazopanib + CG-781 Sensitive: C3 – Early Trials
PBRM1 underexpression PBRM1 underexpression	Renal Cell Carcinoma RCC	sorafenib Resistant: C3 – Early Trials
PBRM1 overexpression PBRM1 overexpression	Renal Cell Carcinoma RCC	sorafenib Sensitive: C3 – Early Trials
PD-1-H PD-1-H	Renal Cell Carcinoma RCC	sunitinib Resistant: C3 – Early Trials
SETD2 mutation SETD2 mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	Immunotherapy Resistant: C3 – Early Trials
ERVE-4 expression ERVE-4 expression	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials
HAVCR2 expression HAVCR2 expression	Renal Cell Carcinoma RCC	nivolumab + ipilimumab Sensitive: C3 – Early Trials
HAVCR2 expression HAVCR2 expression	Renal Cell Carcinoma RCC	nivolumab Sensitive: C3 – Early Trials
VEGFA-H VEGFA-H	Renal Cell Carcinoma RCC	pazopanib Resistant: C3 – Early Trials
CXCL12-H CXCL12-H	Renal Cell Carcinoma RCC	pazopanib Resistant: C3 – Early Trials
SPP1-L SPP1-L	Renal Cell Carcinoma RCC	pazopanib Sensitive: C3 – Early Trials
HGF-L HGF-L	Renal Cell Carcinoma RCC	pazopanib Sensitive: C3 – Early Trials
CXCL8-L CXCL8-L	Renal Cell Carcinoma RCC	pazopanib Sensitive: C3 – Early Trials
IL6-L IL6-L	Renal Cell Carcinoma RCC	pazopanib Sensitive: C3 – Early Trials
PAI1-H PAI1-H	Renal Cell Carcinoma RCC	axitinib Resistant: C3 – Early Trials
HGF expression HGF expression	Renal Cell Carcinoma RCC	lenvatinib Sensitive: C3 – Early Trials
IL18 expression IL18 expression	Renal Cell Carcinoma RCC	lenvatinib Sensitive: C3 – Early Trials
ANGPT2 expression ANGPT2 expression	Renal Cell Carcinoma RCC	lenvatinib Sensitive: C3 – Early Trials

Renal Cell Carcinoma

Associations(229)

Associations
(229)